Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04301661 · ClinicalTrials.gov registry record
Cellular Pharmacology and Platelet Effects of Abacavir and Lamivudine Anabolites
A clinical trial, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- 25
- Enrollment target
NCT04301661: Completed study, sponsored by University of Colorado, Denver.
NCT04301661 is a clinical trial that has completed, run by University of Colorado, Denver. The registered enrollment target is 25 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04301661 has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- 25 participants
- Enrollment target
Study Summary
This study will evaluate the intracellular pharmacokinetics and platelet effects of abacavir (ABC), lamivudine (3TC), tenofovir alafenamide (TAF), and emtricitabine (FTC) in persons living with HIV that are receiving these medications as part of standard HIV care. Participants remaining on ABC/3TC- or TAF/FTC-containing therapy will be on study for 4 weeks, and will have two visits: a screening visit and one short PK visit consisting of a single blood draw at week 4. Participants switching from their ABC/3TC-containing therapy will be on study for 3 weeks, and will have nine visits: a screening visit and 8 short PK visits consisting of a single blood draw at Day 0, 1, 3, 7, 10, 14, 18, and 21.
Primary Outcome
Based on drug concentrations measured at week 4
Interventions
- OTHER Blood collection
- DRUG Switch
- DRUG Tenofovir alafenamide/emtricitabine
- DRUG Abacavir/lamivudine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2020-03-06 |
| Est. Completion | 2021-12-17 |
What the finished NCT04301661 record still lists
NCT04301661 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 25 participants, a relatively small participant target.
The record links to 0 conditions, and to 4 interventions - of which Blood collection is the first listed.
NCT04301661 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04301661 about?
NCT04301661 is a clinical study titled "Cellular Pharmacology and Platelet Effects of Abacavir and Lamivudine Anabolites". This study will evaluate the intracellular pharmacokinetics and platelet effects of abacavir (ABC), lamivudine (3TC), tenofovir alafenamide (TAF), and emtricitabine (FTC) in persons living with HIV that are receiving these medications as part of standard HIV care. Participants remaining on ABC/3TC-...
What is the current status of trial NCT04301661?
This trial is currently completed. The enrollment target is 25 participants. The study started on 2020-03-06. Estimated completion is 2021-12-17.
What interventions are being tested in trial NCT04301661?
The interventions under investigation include: Blood collection (OTHER), Switch (DRUG), Tenofovir alafenamide/emtricitabine (DRUG), Abacavir/lamivudine (DRUG).
Who is sponsoring clinical trial NCT04301661?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI